Clinical Trials Browser

Terminated × NIH × sacituzumab govitecan × Clear all

NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Phase 2 Terminated

2 enrolled 7 charts

Recurrence